Cargando…
Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
(1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem monotherapy and microbiological outcome in a case series of urological patients with documented Gram-negative infections. (2...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525318/ https://www.ncbi.nlm.nih.gov/pubmed/37760685 http://dx.doi.org/10.3390/antibiotics12091388 |
_version_ | 1785110755289333760 |
---|---|
author | Berrino, Pasquale Maria Gatti, Milo Rinaldi, Matteo Brunocilla, Eugenio Viale, Pierluigi Pea, Federico |
author_facet | Berrino, Pasquale Maria Gatti, Milo Rinaldi, Matteo Brunocilla, Eugenio Viale, Pierluigi Pea, Federico |
author_sort | Berrino, Pasquale Maria |
collection | PubMed |
description | (1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem monotherapy and microbiological outcome in a case series of urological patients with documented Gram-negative infections. (2) Methods: Patients admitted to the urology ward who were treated with CI piperacillin–tazobactam or meropenem monotherapy for documented Gram-negative infections and underwent real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program from June 2021 to May 2023 were retrospectively retrieved. Average steady-state (C(ss)) piperacillin–tazobactam and meropenem concentrations were determined, and the free fractions (fC(ss)) were calculated. Optimal PK/PD target attainments were defined as an fC(ss)/MIC ratio >4 for CI meropenem and an fC(ss)/MIC ratio of piperacillin >4 coupled with an fC(ss)/C(T) ratio for tazobactam >1 for piperacillin–tazobactam (joint PK/PD target). The relationship between beta-lactam PK/PD targets and microbiological outcome was explored. (3) Results: Sixteen urologic patients with documented Gram-negative infections (62.5% complicated urinary tract infections (cUTI)) had 30 TDM-guided ECPAs. At first TDM assessment, beta-lactam dosing adjustments were recommended in 11 out of 16 cases (68.75%, of which 62.5% decreases and 6.25% increases). Overall, beta-lactam dosing adjustments were recommended in 14 out of 30 ECPAs (46.6%). Beta-lactam PK/PD target attainments were optimal in 100.0% of cases. Microbiological failure occurred in two patients, both developing beta-lactam resistance. (4) Conclusion: A TDM-guided ECPA program may allow for optimizing beta-lactam treatment in urologic patients with documented Gram-negative infections, ensuring microbiological eradication in most cases. |
format | Online Article Text |
id | pubmed-10525318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105253182023-09-28 Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections Berrino, Pasquale Maria Gatti, Milo Rinaldi, Matteo Brunocilla, Eugenio Viale, Pierluigi Pea, Federico Antibiotics (Basel) Article (1) Objectives: To describe the relationship between pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) piperacillin–tazobactam or meropenem monotherapy and microbiological outcome in a case series of urological patients with documented Gram-negative infections. (2) Methods: Patients admitted to the urology ward who were treated with CI piperacillin–tazobactam or meropenem monotherapy for documented Gram-negative infections and underwent real-time therapeutic drug monitoring (TDM)-guided expert clinical pharmacological advice (ECPA) program from June 2021 to May 2023 were retrospectively retrieved. Average steady-state (C(ss)) piperacillin–tazobactam and meropenem concentrations were determined, and the free fractions (fC(ss)) were calculated. Optimal PK/PD target attainments were defined as an fC(ss)/MIC ratio >4 for CI meropenem and an fC(ss)/MIC ratio of piperacillin >4 coupled with an fC(ss)/C(T) ratio for tazobactam >1 for piperacillin–tazobactam (joint PK/PD target). The relationship between beta-lactam PK/PD targets and microbiological outcome was explored. (3) Results: Sixteen urologic patients with documented Gram-negative infections (62.5% complicated urinary tract infections (cUTI)) had 30 TDM-guided ECPAs. At first TDM assessment, beta-lactam dosing adjustments were recommended in 11 out of 16 cases (68.75%, of which 62.5% decreases and 6.25% increases). Overall, beta-lactam dosing adjustments were recommended in 14 out of 30 ECPAs (46.6%). Beta-lactam PK/PD target attainments were optimal in 100.0% of cases. Microbiological failure occurred in two patients, both developing beta-lactam resistance. (4) Conclusion: A TDM-guided ECPA program may allow for optimizing beta-lactam treatment in urologic patients with documented Gram-negative infections, ensuring microbiological eradication in most cases. MDPI 2023-08-31 /pmc/articles/PMC10525318/ /pubmed/37760685 http://dx.doi.org/10.3390/antibiotics12091388 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Berrino, Pasquale Maria Gatti, Milo Rinaldi, Matteo Brunocilla, Eugenio Viale, Pierluigi Pea, Federico Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections |
title | Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections |
title_full | Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections |
title_fullStr | Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections |
title_full_unstemmed | Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections |
title_short | Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections |
title_sort | pharmacokinetic/pharmacodynamic target attainment of continuous infusion piperacillin–tazobactam or meropenem and microbiological outcome among urologic patients with documented gram-negative infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10525318/ https://www.ncbi.nlm.nih.gov/pubmed/37760685 http://dx.doi.org/10.3390/antibiotics12091388 |
work_keys_str_mv | AT berrinopasqualemaria pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections AT gattimilo pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections AT rinaldimatteo pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections AT brunocillaeugenio pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections AT vialepierluigi pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections AT peafederico pharmacokineticpharmacodynamictargetattainmentofcontinuousinfusionpiperacillintazobactamormeropenemandmicrobiologicaloutcomeamongurologicpatientswithdocumentedgramnegativeinfections |